Ashkon Software



NLNK - NewLink Genetics Corporation

NLNK Stock Chart

NLNK Profile

NewLink Genetics Corporation logo

NewLink Genetics Corporation (NLNK) is a biopharmaceutical company that is focused on discovering, developing, and commercializing novel immuno-oncology products. The company's pipeline includes a range of immunotherapeutic candidates designed to stimulate the body's immune system to fight cancer.

NewLink Genetics has several product candidates in various stages of clinical development, including NLG207, a nanoparticle liposome formulation of the chemotherapy agent docetaxel, NLG802, a prodrug of indoximod, and NLG919, an IDO pathway inhibitor. The company also has several preclinical candidates in development, including a cancer vaccine designed to target the survivin protein.

NewLink Genetics has partnerships with several other biopharmaceutical companies, including Roche and Merck, to develop and commercialize its products. The company is headquartered in Ames, Iowa, and was found


Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer